A phase II marker identification trial for Tarceva in second line NSCLC patients

Update Il y a 4 ans
Reference: EUCTR2004-005096-42

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is the identification of differentially expressed genes that are predictive for benefit of Tarceva treatment.


Inclusion criteria

  • Advanced (stage IIIb and IV) non small cell lung cancer